Disparate Effects of Diabetes and Hyperlipidemia on Experimental Kidney Disease

Anna M D Watson1,2, Eleanor A M Gould2, Sarah C Moody2

  • 1Central Clinical School, Monash University, Melbourne, VIC, Australia.

Insights

Diabetes significantly impacts kidney health, causing chronic kidney disease. This study found that diabetes, not high-fat diets, drives kidney injury through factors beyond lipids.

Area of Science:

  • Nephrology
  • Endocrinology
  • Metabolic Syndrome

Background:

  • Diabetes mellitus is a leading cause of chronic kidney disease (CKD) globally.
  • Hyperglycemia and advanced glycation endproducts are key contributors to diabetic kidney disease (DKD).
  • The role of lipids in DKD pathogenesis remains incompletely understood.

Purpose of the Study:

  • To investigate and compare the effects of diabetes and hyperlipidemia on kidney injury.
  • To evaluate these effects in two distinct mouse models: C57BL/6 and apolipoprotein E knockout (apoE KO) mice.
  • To elucidate the specific roles of hyperglycemia versus lipid dysregulation in driving renal pathology.

Main Methods:

  • Induction of diabetes using streptozotocin in C57BL/6 and apoE KO mice.
  • Feeding a high-fat western diet to control and apoE KO mice for 20 weeks.
  • Assessment of kidney injury markers including kidney-to-body weight ratio, urinary albumin excretion (UAE), and fibronectin expression.

Main Results:

  • Diabetes induction led to elevated glycated hemoglobin and increased kidney-to-body weight ratio in both mouse strains.
  • ApoE deficiency and western diet exacerbated plasma cholesterol and triglyceride levels.
  • Urinary albumin excretion and extracellular matrix accumulation were significantly increased in diabetic mice, but not by the western diet.
  • Renal fibronectin mRNA expression, a marker of fibrosis, increased in diabetic mice.

Conclusions:

  • Diabetes, characterized by hyperglycemia, is a primary driver of kidney injury and fibrosis.
  • Hyperlipidemia, induced by apoE deficiency or western diet, did not significantly contribute to kidney injury markers like UAE.
  • Pathological features of diabetic kidney disease are primarily driven by non-lipid-related factors within the diabetic milieu.

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
444
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
446
External Anatomy of the Kidney01:21

External Anatomy of the Kidney

The kidneys are a pair of bean-shaped organs in the human body that play a critical role in maintaining overall health. They filter out waste products from the blood, regulate blood pressure, maintain electrolyte balance, and stimulate the production of red blood cells.
The kidneys are located in the retroperitoneal space on either side of the vertebral column, protected posteriorly by the 11th and 12th ribs. The right kidney sits slightly lower than the left owing to the presence of the liver...
3.0K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
145